MedTrace Logo

Effects of Coenzyme Q10 (CoQ) in Parkinson Disease

NCT00740714 · Status: TERMINATED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 600

Last updated 2013-01-31

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to evaluate the safety and effectiveness of high dosages of Coenzyme Q10 in slowing clinical decline in people who have early Parkinson disease.

Conditions

  • Parkinson Disease

Interventions

DRUG

Coenzyme Q10 with vitamin E

2400 mg dose - eight 300 mg Coenzyme Q10 chewable wafers taken orally four times a day; 1200 mg dose - four 300 mg Coenzyme Q10 and four placebo chewable wafers taken orally four times a day.

DRUG

placebo with vitamin E

placebo or an inactive substance (with vitamin E 1200 IU/day); Placebo - eight chewable wafers taken orally four times a day.

Sponsors & Collaborators

  • National Institute of Neurological Disorders and Stroke (NINDS)

    collaborator NIH

  • University of Rochester

    collaborator OTHER

  • Weill Medical College of Cornell University

    lead OTHER

Principal Investigators

  • M. Flint Beal, MD · Weill Medical College of Cornell University, New York Hospital Department of Neurology

  • David Oakes, PhD · University of Rochester, Department of Biostatistics

  • Ira Shoulson, MD · University of Rochester, Clinical Trials Coordination Center

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
30 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2008-12-31
Primary Completion
2011-08-31
Completion
2011-08-31

Countries

  • United States
  • Canada

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00740714 on ClinicalTrials.gov